News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,118 Results
Type
Article (40872)
Company Profile (267)
Press Release (679969)
Multimedia
Podcasts (80)
Webinars (17)
Section
Business (204652)
Career Advice (2022)
Deals (35531)
Drug Delivery (110)
Drug Development (81370)
Employer Resources (173)
FDA (16403)
Job Trends (14941)
News (346348)
Policy (32723)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2565)
Accelerated approval (31)
Adcomms (24)
Allergies (137)
Alliances (49575)
ALS (167)
Alzheimer's disease (1659)
Antibody-drug conjugate (ADC) (305)
Approvals (16667)
Artificial intelligence (501)
Autoimmune disease (143)
Automation (37)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (187)
Biotechnology (174)
Bladder cancer (157)
Brain cancer (55)
Breast cancer (632)
Cancer (4752)
Cardiovascular disease (395)
Career advice (1707)
Career pathing (35)
CAR-T (275)
CDC (44)
Celiac Disease (2)
Cell therapy (729)
Cervical cancer (36)
Clinical research (69490)
Collaboration (1666)
Company closure (4)
Compensation (1143)
Complete response letters (52)
COVID-19 (2707)
CRISPR (87)
C-suite (811)
Cystic fibrosis (143)
Data (6151)
Decentralized trials (2)
Denatured (25)
Depression (130)
Diabetes (495)
Diagnostics (6669)
Digital health (44)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (242)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (227)
Earnings (90037)
Editorial (55)
Employer branding (21)
Employer resources (151)
Events (117180)
Executive appointments (958)
FDA (19480)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1444)
Gene editing (191)
Generative AI (42)
Gene therapy (582)
GLP-1 (962)
Government (4651)
Grass and pollen (6)
Guidances (383)
Healthcare (18868)
HIV (55)
Huntington's disease (44)
IgA nephropathy (81)
Immunology and inflammation (244)
Immuno-oncology (53)
Indications (104)
Infectious disease (2965)
Inflammatory bowel disease (186)
Inflation Reduction Act (14)
Influenza (110)
Intellectual property (242)
Interviews (315)
IPO (16638)
IRA (49)
Job creations (3641)
Job search strategy (1427)
JPM (56)
Kidney cancer (15)
Labor market (83)
Layoffs (545)
Leadership (30)
Legal (7948)
Liver cancer (91)
Longevity (14)
Lung cancer (639)
Lymphoma (372)
Machine learning (42)
Management (59)
Manufacturing (777)
MASH (161)
Medical device (13754)
Medtech (13806)
Mergers & acquisitions (19950)
Metabolic disorders (1251)
Multiple sclerosis (156)
NASH (16)
Neurodegenerative disease (307)
Neuropsychiatric disorders (86)
Neuroscience (2866)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4509)
Now hiring (65)
Obesity (587)
Opinion (257)
Ovarian cancer (164)
Pain (196)
Pancreatic cancer (222)
Parkinson's disease (279)
Partnered (33)
Patents (486)
Patient recruitment (471)
Peanut (55)
People (58807)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21665)
Phase 2 (30584)
Phase 3 (22789)
Pipeline (5090)
Policy (278)
Postmarket research (2564)
Preclinical (9190)
Press Release (64)
Prostate cancer (234)
Psychedelics (47)
Radiopharmaceuticals (277)
Rare diseases (814)
Real estate (5954)
Recruiting (69)
Regulatory (24417)
Reports (51)
Research institute (2383)
Resumes & cover letters (351)
Rett syndrome (27)
RNA editing (16)
RSV (76)
Schizophrenia (146)
Series A (237)
Series B (184)
Service/supplier (11)
Sickle cell disease (95)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3612)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (84)
The Weekly (53)
Vaccines (983)
Venture capital (86)
Weight loss (377)
Women's health (87)
Worklife (18)
Date
Today (37)
Last 7 days (593)
Last 30 days (1976)
Last 365 days (29759)
2026 (2848)
2025 (30172)
2024 (35215)
2023 (40075)
2022 (51174)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32108)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (736)
Alabama (83)
Alaska (7)
Arizona (305)
Arkansas (13)
Asia (39185)
Australia (6405)
California (11157)
Canada (3251)
China (1082)
Colorado (471)
Connecticut (469)
Delaware (332)
Europe (84415)
Florida (1662)
Georgia (353)
Hawaii (3)
Idaho (61)
Illinois (852)
India (62)
Indiana (513)
Iowa (22)
Japan (417)
Kansas (125)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1369)
Massachusetts (7993)
Michigan (319)
Minnesota (622)
Mississippi (5)
Missouri (125)
Montana (31)
Nebraska (28)
Nevada (121)
New Hampshire (78)
New Jersey (2967)
New Mexico (28)
New York (2942)
North Carolina (1436)
North Dakota (8)
Northern California (5436)
Ohio (329)
Oklahoma (21)
Oregon (41)
Pennsylvania (2252)
Puerto Rico (22)
Rhode Island (47)
South America (1107)
South Carolina (65)
South Dakota (1)
Southern California (4342)
Tennessee (172)
Texas (1722)
United States (39557)
Utah (333)
Vermont (1)
Virginia (256)
Washington D.C. (81)
Washington State (913)
West Virginia (4)
Wisconsin (106)
Wyoming (2)
721,118 Results for "neuronascent inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Neuronascent Announces Progress for Lead Candidate NNI-362: Publication of Phase 1a Clinical Trial Results and FDA Grants Waiver of Fee for Canine Cognitive Disorder 2025 Submissions
August 13, 2025
·
3 min read
Drug Development
Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease
Neuronascent Inc., a privately-held neuron regeneration therapeutics company, announced that the National Institute of Aging, has awarded a U01 grant to Neuronascent, with the CEO, Dr. Judith Kelleher-Andersson being the principal investigator.
August 22, 2023
·
3 min read
BioCapital
Neuronascent Announces the Expansion of its Board of Directors
Neuronascent Inc., a clinical-stage, neuron generating, biopharmaceutical company, is pleased to announce the addition of industry leader Emer Leahy, Ph.D., MBA, to its Board of Directors.
April 12, 2023
·
3 min read
BioCapital
Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease Investigational Therapy, NNI-362
Neuronascent Inc., announced its abstract titled, Clinical Stage Alzheimer’s therapy, NNI-362 Promotes TH+ Neurons Associated with a Reversal of Motor Deficits in AAV-Alpha Synuclein Model, Leaving Alpha Synuclein Unchanged has been accepted for a poster presentation at the Alzheimer’s Association International Conference to be held in Amsterdam, Holland, on July 19, 2023.
June 28, 2023
·
3 min read
Press Releases
Repare Announces Completion of Acquisition by XenoTherapeutics, Inc.
January 29, 2026
·
6 min read
Press Releases
Encision Inc. Announces Fiscal 2026 Third Quarter Results
February 4, 2026
·
1 min read
Press Releases
Therma Bright Inc. Investee Company, InStatin Expands its Inhaled Statin Programs to include COPD (Chronic Obstructive Pulmonary Disease) as its Lead Indication.
Includes Asthma in its strategic plans and Strengthens its Team in 2024-2025
December 18, 2025
·
5 min read
Press Releases
ABS Bio, Inc. acquires Cureline, Inc. to strengthen support of biopharma drug discovery
January 7, 2026
·
1 min read
Press Releases
DW Healthcare Partners Announces Sale of LKC Technologies to AMETEK, Inc.
February 3, 2026
·
2 min read
Policy
Neuronascent Receives FDA Rare Pediatric Drug Designation for NNI-351 Treatment for Fragile X Syndrome
Neuronascent Inc. announced that the US Food and Drug Administration granted rare pediatric designation for NNI-351 for Fragile X syndrome.
May 24, 2022
·
3 min read
1 of 72,112
Next
